|1.||Grover, Gary J: 2 articles (01/2008 - 01/2008)|
|2.||Chang, Hsin-Yi: 1 article (04/2008)|
|3.||Hsu, Chun-Hua: 1 article (04/2008)|
|4.||Juan, Hsueh-Fen: 1 article (04/2008)|
|5.||Huang, Tsui-Chin: 1 article (04/2008)|
|6.||Chang, King-Jen: 1 article (04/2008)|
|7.||Kuo, Wen-Hung: 1 article (04/2008)|
|8.||Marone, Palma Ann: 1 article (01/2008)|
|9.||Koetzner, Lee: 1 article (01/2008)|
|10.||Malm, Johan: 1 article (01/2008)|
01/01/2008 - "Based on studies with the nonselective (inhibit both synthase and hydrolase activity) inhibitors aurovertin B and oligomycin B reduce the rate of ATP depletion during ischemia, showing that IF-1 does not completely block hydrolase activity. "
01/01/2008 - "This "inefficient" hydrolysis of ATP consumes 90% of ATP consumed during ischemia as shown with non-selective ATPase inhibitors oligomycin and Aurovertin B. "
|4.||Breast Neoplasms (Breast Cancer)
04/01/2008 - "Aurovertin B inhibits proliferation of breast cancer cells by inducing apoptosis and arresting cell cycle at the G0/G1 phase. "
04/01/2008 - "Aurovertin B, an ATP synthase inhibitor, has strong inhibition on the proliferation of several breast cancer cell lines, but little influence on the normal cell line MCF-10A. "
|1.||Adenosine Triphosphate (ATP)
|4.||Adenosine Triphosphatases (ATPase)
|1.||Drug Therapy (Chemotherapy)